IZOTROPIC
CORPORATION



INVESTOR PRESENTATION

For illustrative purposes only. IzoView is not yet approved for sale

IZOTROPIC OVERVIEW

The only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers.

BREAST CT EVOLUTION

- $20M spent on R&D to date via government grants
- Performing prototypes and ongoing clinical trials
- Published journal articles
- Proprietary AI software

GROWING MARKET

- Breast imaging market growing from $3.7B to $5.4B by 2025
- Imaging and diagnostic procedure costs after screening mammography in the US is over $8B/ year

REGULATORY

- Patient and payor demand for new technology
- US FDA pre-submission meeting completed
- Engaging additional jurisdictions

PLATFORM SYSTEM

- Multiple indications for use underway and planned
- Accessory products
- Screening, diagnostic, treatment capabilities

MARKET ADOPTION

- Insurance payor discussions initiated and ongoing
- Targeted advocacy groups
- Engaging US hospitals for clinical study

CORPORATE

- 51.8M shares issued
- $54M fully diluted
- 4M raised in 2022

5TH GENERATION DEVICE

First device for commercialization

Proof of Concept Units by Dr. John M. Boone at UC Davis

- Four successive laboratory prototypes
- Over 600 patients imaged in a clinical study validating the technology
- Second ongoing clinical study with 400 patients underway

IzoView for Commercialization by Izotropic

- 5th unit under development with latest hardware and software



For illustrative purposes only. IzoView is not yet approved for sale

LICENSED TECHNOLOGY & INTELLECTUAL PROPERTY

GLOBAL LICENSING RIGHTS

- Exclusive worldwide licensing rights to Breast CT through an agreement with The Regents of The University of California
- Developed over 20 years by principal technology founder and company director Dr. John M. Boone
- Commercialization initiated in 2017

PATENTS

- Portfolio of 10 U.S and international patents and patent applications
- New patent filings and prosecution ongoing

For illustrative purposes only. IzoView is not yet approved for sale

BREAST CANCER IS NOW THE MOST COMMON FORM OF THE DISEASE

U.S. Breast Cancer Landscape Facts.

41M BREASTS SCANS IN 2019

- Screening mammography misses 1/ 5 cancers
- >8,500 MSQA Certified imaging centers and >23,000 mammography and tomosynthesis certified units installed
- Cost of follow-up diagnostic imaging and procedures after screening is $8B annually

1.4M BREAST BIOPSIES/ YEAR

- 71% of breast biopsies are negative
- The cumulative cost of negative biopsies is $2.2B per year

280K NEW BREAST CANCER CASES / YEAR

- 1 in 8 women will be diagnosed with breast cancer in their lifetime, 1 in 39 will die
- Estimated 43,600 will die from breast cancer in 2021
- There are more than 3.8M women that have been breast cancer survivors in the U.S.

40% WOMEN HAVE DENSE BREASTS

- Breast cancer risk increases with density
- 2019 FDA mandate to report patients' breast density
- Breast CT imaging is ideal for density measurements

DIAGNOSTIC MAMMOGRAPHY CHALLENGES

Limitations of the current standard of care.

Mammography machine pictured.
Tomosynthesis design similar.

CONTINUAL BREAST COMPRESSION

- Technician manipulation of the breast for multiple imaging views
- 46% of patient non-compliance is due to pain
- Concerns with breast implants (ie. discomfort and rupture)

REQUIRES TECHNICAL SKILL AND LONG WORK FLOW

- Up to 12 individual views
- Up 20 seconds of compression per view
- Can take 20-45 mins to capture all images
- Significant technical skills are required

DISTORTED IMAGES

- Distorts anatomical structures
- No differentiation macro or microcalcifications (breast cancer indicators)
- Does not use contrast for tumor visualization
- Mammography sensitivity is 73%, and only 44% in patients with dense breasts
- 40% of patients have dense breasts

IZOVIEW BREAST CT

A whole new experience for patients, radiologists and providers.

NO BREAST COMPRESSION

Natural breast orientation preserved, no pain or discomfort, very comfortable face down view, excellent visualization with contrast

PATIENT EMPOWERMENT

Patient places own breast in imaging cup, no breast handling by technician

SHORT WORK FLOW

Increased patient throughput with a 10 second scan, data set in under 30 seconds



HIGH RESOLUTION TRUE 3D IMAGING

May provide more accurate margin analysis (viewing edges of a tumor), lesion characterization (determining the qualities of an abnormality), and higher spatial resolution (the imaging ability to differentiate between internal breast structures)

IMAGE QUALITY

Approximately 500 image views in 10 seconds (depending on the length of the breast), radiation dose is low and comparable to 2-view mammography, is ideal for imaging patients with dense breast tissue

For illustrative purposes only. IzoView is not yet approved for sale

SOLVING AN UNMET NEED

Images below are of the same breast.

Mammography **Tomosynthesis** IzoView



2D Image

2.5D Image

True 3D, 360 degree

1 single image slice of the 500 obtained

IZOVIEW PLATFORM USES

Making Breast CT an indispensable tool for improving the outcomes of breast cancer.

STEPS TO TREATMENT:	SCREENING	DIAGNOSTIC	BIOPSY	TREATMENT	MONITORING
PLATFORM PRODUCTS:	NEW INDICATIONS	*INITIAL REGULATORY FOCUS*	NEW ACCESSORIES	NEW DEVICES	NEW SOFTWARE
SALES MODELS:	ONE TIME, RENTAL, PAY PER USE		ONE TIME PAYMENT	SUBSCRIPTIONS	

BROAD ENGAGEMENT PREPARING FOR MARKET ENTRANCE

Near-term catalysts across multiple workstreams.

DEVELOPMENT

- AI software modules and hardware accessories to expand **IzoView** platform
- Partnerships to accelerate product development: Deep-learning machine algorithms with Johns Hopkins University School of Medicine

CLINICAL STUDY

- Select Clinical Research Organization (CRO) to run clinical study
- Clinical site selections, ie. major hospitals and clinics

REIMBURSEMENT

- Expanding payor engagement
- Collaborating with payors on secondary clinical study end points to support insurance coverage

INTELLECTUAL PROPERTY

- Continue to file and prosecute patents to support **IzoView** platform
- Screening, diagnostic, biopsy, treatment and monitoring

REGULATORY

- Discussions with jurisdictions outside of U.S.
- Planning for additional indications for use to broaden **IzoView** breast CT platform scope
- Quality Management System implemented

CORPORATE

- Pursuing additional non-dilutive capital, ie. grants and government sponsored capital recovery programs
- Womens health advocacy groups

DIRECTORS & MANAGEMENT

BOB THAST
Interim CEO, Director

Capital markets specialist, strategic planning, business development and finance

JOHN M. BOONE, PHD
Founder & Director

Medical Physicist, Professor, global speaker, text book author, ICRU Commissioner

YOUNES ACHKIRE, PHD
Chief Operating Officer

Medical device R&D expert, managing final design and fabrication of Izoview and future accessory products

ANDREW HERNANDEZ, PHD
Head of Imaging Technology

Biomedical Engineer, world authority on radiation dosimetry for breast CT, mentored by Dr. John Boone

RALPH PROCEVIAT, CPA
Interim CFO, Director

Business, finance and markets operations across Canada, US and Europe

ALI SODAGAR
Director & Legal Advisor

International business law, finance, IP, trademark, copyright, and licensing law

ALEXANDER TOKAMN
Director

Healthcare, Consumer Electronics, Semiconductor and AI sectors for Fortune 100

MEDICAL & SCIENTIFIC ADVISORS

Internationally Recognized Specialists that played vital roles in establishing current standards of breast care.

DR. MARTIN YAFFE, PHD

University of Toronto, SunnyBrook Hospital

Drove the development of **digital mammography**, Member of The Order of Canada

DR. KAREN LINDFORS MD, MPH, FACR

UC Davis

Highly published leading advocate for women's health and xpert in the field of **breast cancer screening** and breast imaging and diagnostics

DR. NORBERT PELC, DSC

Stanford University

Work is focused on improving information content, image quality and the **reduction of radiation dose** in CT examinations

CRAIG SHIMASAKI, PHD, MBA

Northwestern

Co-Founder of 3 **biotech** companies, scientist, author, businessperson and entrepreneur , FDA experienced, focus on diagnostic and therapeutic products

GEORGE BURKETT , M.ENG

UC Davis

Responsible for the detailed design, mechanical and hardware development of 4 **Breast CT** academic and clinical research prototypes

CRAIG ABBEY, PHD

UC Santa Barbara

Evaluated reader studies at the **FDA** for the medical device approvals including Hologic's Digital Breast Tomosynthesis

DR. JEFF SIEWERDSEN, PHD

Johns Hopkins University

Image guided **radiation therapy expert** with focus on new medical imaging technologies

DR. TAO WU, PHD

Harvard University

Development and **commercialization of tomosynthesis** and Full Field Digital Mammography products

DR. SHADI SHAKERI, MD, FSBI

UC Davis

Practicing radiologist sp-ecializing in breast imaging. Has been in charge of the clinical aspects of Breast CT clinical trials since 2017 at UC Davis and has been working breast CT since 2009 .

DISCLAIMER

This document may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions, projections and expectations of the company’s management, business, and its knowledge of the relevant market and economic environment in which it operates. The company has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such they may cause future results of the company’s activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the company nor its shareholders, officers and consultants, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of company securities. Nothing in this document should be deemed to be medical or other advice of any kind. Images are for illustrative purposes only. IzoView is not yet approved for sale.